Dr. Ferraro on the Use of Molecular Profiling in Pancreatic Cancer

Pablo Ferraro, MD
Published: Thursday, Jan 16, 2020



Pablo Ferraro, MD, medical oncologist, Memorial Healthcare System, discusses the use of molecular profiling in pancreatic cancer.

With molecular profiling, researchers may be able to identify potential actionable targets that could lead to additional treatment strategies in pancreatic cancer, explains Ferraro.

A number of preclinical and phase I studies are being done, and further research could lead to larger phase II/III studies.

In other cancers, targeted therapy has revolutionized treatment, Ferraro says. For example, lung cancer was a historically difficult disease to treat, but now there are several effective targeted therapy options for patients. The hope is that, with further research, the same will be true for patients with pancreatic cancer, concludes Ferraro.
SELECTED
LANGUAGE


Pablo Ferraro, MD, medical oncologist, Memorial Healthcare System, discusses the use of molecular profiling in pancreatic cancer.

With molecular profiling, researchers may be able to identify potential actionable targets that could lead to additional treatment strategies in pancreatic cancer, explains Ferraro.

A number of preclinical and phase I studies are being done, and further research could lead to larger phase II/III studies.

In other cancers, targeted therapy has revolutionized treatment, Ferraro says. For example, lung cancer was a historically difficult disease to treat, but now there are several effective targeted therapy options for patients. The hope is that, with further research, the same will be true for patients with pancreatic cancer, concludes Ferraro.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x